RXR激动剂增强莱纳利多米德抗髓瘤活性和T细胞功能,同时保持降血糖效应
Jian Wu1, Xiaobei Wang1, Min Zhang1
1Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA.
Cells
|August 11, 2023
概括
视网膜X受体 (RXR) 激动剂增强了莱纳利多米德的作用.
科学领域:
- 分子生物学分子生物学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 视网膜X受体 (RXR) 与PPAR核受体形成异构体,影响下游基因调节.
- 列纳利多米德是多发性骨髓瘤 (MM) 的关键治疗剂.
研究的目的:
- 为了研究RXR激动剂与莱纳利多米德对抗髓瘤活性和T细胞功能的协同作用.
- 阐明组合疗法的有效性背后的分子机制.
主要方法:
- 在多发性骨髓瘤和Jurkat T细胞系中使用RXR激动剂 (LG100754,贝克萨罗,AGN194204,LG101506).
- 在CRBN中使用过度基因表达和CRISPR/Cas9淘汰.
- 建立了一个异种移植小鼠模型,用于体内疗效评估.
主要成果:
- 组合疗法协同增加了CRBN表达和髓瘤细胞死亡.
- RXR激动剂降低了PPAR与CRBN促进体的结合,减轻了转录抑制.
- RXR激动剂增强了T细胞激活,并减少了疲劳标记.
- 在体内研究证实,LG100754和莱纳利多米德的同时使用增强了抗瘤活性.
- LG100754 持续降低葡萄糖和脂质的作用.
结论:
- RXR激动剂显示出改善莱纳利多米德敏感性和T细胞介导的抗髓瘤反应的潜力.
- 这种组合策略为多发性骨髓瘤治疗提供了一个有希望的方法.
- RXR激动剂也可能在癌症患者中提供代谢益处.
相关概念视频
Glucagon-like Receptor Agonists
358
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
358
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Oral Hypoglycemic Agents: Biguanides and Glitazones
234
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
234
Tumor Immunotherapy
557
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
557
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
195
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
195
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
206
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
206


